Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Agenus Inc (AGEN)

Agenus Inc (AGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 341,018
  • Shares Outstanding, K 134,259
  • Annual Sales, $ 36,780 K
  • Annual Income, $ -159,690 K
  • 60-Month Beta 1.86
  • Price/Sales 9.82
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.33
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.38
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +2.40%
on 07/16/19
3.10 -17.42%
on 06/25/19
-0.10 (-3.76%)
since 06/14/19
3-Month
2.47 +3.64%
on 04/22/19
3.10 -17.42%
on 06/25/19
-0.06 (-2.29%)
since 04/16/19
52-Week
1.54 +66.23%
on 10/30/18
3.88 -34.02%
on 01/18/19
+0.48 (+23.08%)
since 07/16/18

Most Recent Stories

More News
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?

Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AGEN : 2.56 (+0.79%)
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.

AGEN : 2.56 (+0.79%)
NVO : 47.72 (+0.15%)
GILD : 66.94 (-1.66%)
GSK : 41.18 (+0.68%)
Why Is Agenus (AGEN) Down 6.3% Since Last Earnings Report?

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGEN : 2.56 (+0.79%)
MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point

MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that the Company's board of directors...

AGEN : 2.56 (+0.79%)
MDXG : 4.9200 (-2.57%)
PTCI : 0.5500 (+37.50%)
Agenus' (AGEN) Pipeline Progression on Track Amid Competition

Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.

ANIK : 40.77 (+1.07%)
AGEN : 2.56 (+0.79%)
GILD : 66.94 (-1.66%)
AGTC : 3.79 (-0.26%)
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss

Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.

AGEN : 2.56 (+0.79%)
GNMSF : 180.6000 (-2.24%)
GILD : 66.94 (-1.66%)
FCSC : 1.88 (+0.53%)
Agenus (AGEN) Surpasses Q1 Earnings Estimates

Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AGEN : 2.56 (+0.79%)
Agenus: 1Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Agenus Inc. (AGEN) on Thursday reported first-quarter net income of $17.4 million, after reporting a loss in the same period a year earlier.

AGEN : 2.56 (+0.79%)
Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided corporate updates and reported financial...

AGEN : 2.56 (+0.79%)
Agenus, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Agenus, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time.

AGEN : 2.56 (+0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade AGEN with:

Business Summary

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's...

See More

Key Turning Points

2nd Resistance Point 2.64
1st Resistance Point 2.60
Last Price 2.56
1st Support Level 2.51
2nd Support Level 2.46

See More

52-Week High 3.88
Fibonacci 61.8% 2.99
Fibonacci 50% 2.71
Last Price 2.56
Fibonacci 38.2% 2.43
52-Week Low 1.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar